Aveo Pharmaceuticals (NASDAQ: AVEO)
Some price data may be temporarily unavailable.
Aveo Pharmaceuticals Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Aveo Pharmaceuticals Company Info
AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.
News & Analysis
Why AVEO Oncology Stock Is Crashing Today
Bad news from the FDA caused investors to head for the hills.
Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
Why AVEO Pharmaceuticals Stock Tanked Last Month
The company's meager cash position is worrying investors.
Why AVEO Pharmaceuticals, Inc. Stock Perked Up in September
AVEO is close to a key clinical readout that could prove to be a major catalyst for its stock.
Why AVEO Pharmaceuticals Inc. Rocketed Higher Today
Hint: It had nothing to do with the press release. The biotech is presenting at a few upcoming conferences, but only one really matters.
Here's Why AVEO Pharmaceuticals Inc. Jumped 40% Higher in August
Investors jump in ahead of expected clinical trial data.
Here's Why AVEO Pharmaceuticals Inc. Jumped Today
Investors are buying into the company's explanation for a delay in clinical trial data.
Here's Why AVEO Pharmaceuticals Inc. Plummeted Today Without Issuing a Press Release
Sometimes you've got to dig into SEC documents to find the answer.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.